Gen2NCE - a genomics-driven platform for novel bioactive natural product discovery
Lead Research Organisation:
University of Warwick
Department Name: Chemistry
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
People |
ORCID iD |
| Gregory Challis (Principal Investigator) |
| Description | The aim of this project was to obtain a full market and IP landscape on technology that was developed during a previous BBSRC-funded project. We have found that there are no existing filed patents that would prevent us from using our technology in an industrial setting. Also from the market research that was performed in this project we have learnt a lot about the costs of developing new pharmaceuticals and agrochemicals. This has allowed us to position our technology to allow us to spin out a company to support these two industries. We were also able to begin some early discussions with a range of agrochemical partners. From the findings of this grant we were able to apply for a BBSRC follow on fund grant to allow us to develop specific aspects of our platform. |
| Exploitation Route | Using the results of this project and with further support from ICURe and the Warwick impact Fund we have spun out a new company Erebagen, which will be looking to exploit the technology to support drug and agrochemical discovery. We have been able to apply for Innovate UK follow on funding to allow us to begin activities as a company. The IP landscaping work performed in this grant has demonstrated key areas of our technology where we have an advantage over others working in the sector and in July 2020 we filed a patent application to protect elements of the technology. |
| Sectors | Agriculture, Food and Drink,Pharmaceuticals and Medical Biotechnology |
| Description | To establish a spin out company. |
| First Year Of Impact | 2020 |
| Sector | Agriculture, Food and Drink,Pharmaceuticals and Medical Biotechnology |
| Impact Types | Economic |
| Description | GEN2NCE - a synthetic biology platform for natural product discovery |
| Amount | £198,477 (GBP) |
| Funding ID | BB/T017163/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 03/2022 |
| Description | ICURe Follow on Funding Grant |
| Amount | £209,834 (GBP) |
| Funding ID | 44930 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 08/2023 |
| Company Name | EREBAGEN LTD |
| Description | Our innovation enables us to engineer soil bacteria to produce new bioactive natural product compounds with hit rates 20x-better than synthetic chemicals and create structural variants of bioactive molecules. Our developed platform has applications in several sectors including pharmaceutical and agrochemical - to discover and develop new natural products into new medicines and crop protection compounds. |
| Year Established | 2020 |
| Impact | 2 FTE scientific post currently in the company. |
| Website | https://uk.linkedin.com/company/erebagen?trk=public_profile_topcard-current-company |